Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.4.1 (
phosphodiesterase
)
18,767
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
(Bu)2cAMP inhibits the action of testicular
Mullerian inhibiting substance
(
MIS
) in vitro, but it is unknown whether the intracellular nucleotide diminishes production of
MIS
by the testis or interferes with its action at the Mullerian duct. When added to the 14 1/2-day old rat embryo Mullerian duct in organ culture, (Bu)2cAMP (0.1 or 1.0 mM) inhibited regression caused by biologically active exogenous
MIS
fractions, as well as that produced by the fetal testis (1.0 mM). Dibutyryl cyclic guanosine 3',5'-monophosphate was ineffective against exogenous
MIS
fractions or the fetal testis. The
phosphodiesterase
inhibitor, methyl-isobutyl-xanthine, had the same inhibitory effect on the
MIS
-fraction (0.1 or 1.0 mM), as well as against
MIS
secreted from the fetal testis (1.0 mM). Theophylline at 1.0 mM inhibited the action of the
MIS
fraction. The presence of (Bu)2cAMP in the medium was required for at least the first 24 h of the 72-h incubation to significantly inhibit
MIS
action. These results indicate that intracellular cAMP inhibits the action of
MIS
at the Mullerian duct itself by a potentially reversible change in the cells. We speculate that cAMP may act by altering the state of differentiation in the cells, perhaps by mediating phosphorylation of intracellular (and extracellular) proteins.
...
PMID:Cyclic adenosine 3',5'-monophosphate modulation of mullerian duct regression. 620 48